Insurance status impacts survival of hepatocellular carcinoma patients after liver resection

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 16; pp. 17037 - 17046
• Main Authors: Qiu, Zhancheng, Qi, Weili, Wu, Youwei, Li, Lingling, Li, Chuan
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01-08-2023; John Wiley and Sons Inc; Wiley
• Subjects: Bilirubin; Cancer therapies; Comorbidity; Confounding (Statistics); Health insurance; Hepatectomy; Hepatocellular carcinoma; insurance; Insurance coverage; Laparoscopy; Liver cancer; Medical prognosis; Microvasculature; Patients; Portal vein; Public health; Risk assessment; Surgery; Survival; Thrombosis; Tumors; α-Fetoprotein; China; insurance; hepatectomy; hepatocellular carcinoma; survival
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.6339

Background
This study intends to examine the effect of public insurance status on survival outcomes of HCC patients after liver resection in China.
Methods
We divided 2911 HCC patients after liver resection included in our study into the Urban Employed‐based Medical Insurance group (UEBMI group, n = 1462) and the non‐Urban Employed‐based Medical Insurance group (non‐UEBMI group, n = 1449). A propensity score matching (PSM) analysis was used to control confounding factors. Overall survival (OS) was estimated by Kaplan–Meier curves and Cox proportional hazard models based on variables screened by Lasso regression. Competing risk analysis was used to analyze cancer‐specific survival (CSS).
Results
UEBMI group had more male patients (p = 0.031), patients in the UEBMI group were older (p < 0.001) and had lower Charlson Comorbidity Index scores (CCI score, p < 0.001). Meanwhile, patients in the UEBMI group had better liver function (albumin‐bilirubin grade I [ALBI I], p < 0.001) and lower tumor burden (α‐fetoprotein [AFP], p = 0.009; Barcelona Clinic Liver Cancer stage [BCLC], p = 0.026; Milan criteria, p < 0.001; tumor size, p < 0.001; microvascular invasion [MVI], p = 0.030; portal vein tumor thrombosis [PVTT], p = 0.002). More patients in the UEBMI group received laparoscopic surgery (p = 0.024) and adjuvant transarterial chemoembolization (TACE, p < 0.001). After PSM, patients in the two matched groups had similar characteristics. Patients with recurrent HCC in the UEBMI were more likely to receive curative therapy (p < 0.001) and less likely to receive supportive care (p < 0.001). HCC patients after liver resection in the non‐UEBMI group had a worse OS before (p < 0.0001) and after PSM (p = 0.002). [Correction added on August 16, 2023 after first online publication. The p value has been updated in the preceding sentence.] In our Lasso‐Cox risk regression model, public health insurance status was an independent factor linked with OS (non‐UEBMI vs. UEBMI, hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 1.12–1.46; p < 0.001). In the competing risk analysis, patients in the UEBMI group had a lower cumulative incidence of CSS before (p < 0.001) and after PSM (p = 0.001), and public insurance status of HCC patients after liver resection remained independently associated with CSS (non‐UEBMI vs. UEBMI; HR:1.36; 95% CI: 1.18–1.58; p < 0.001).
Conclusions
Underinsured HCC patients after liver resection had worse survival outcomes. Less access to care for underinsured patients may explain the difference in survival, but the corresponding conclusions need to be further explored.